Antipruritic mechanisms of topical E6005, a phosphodiesterase 4 inhibitor: Inhibition of responses to proteinase-activated receptor 2 stimulation mediated by increase in intracellular cyclic AMP

Journal of Dermatological Science

Volumn 76, Issue 3, 2014, Pages 206-213

  Andoh, Tsugunobu ^a   Kuraishi, Yasushi ^a  

^a UNIVERSITY OF TOYAMA   (Japan)

Author keywords

CAMP; Itch; Phosphodiesterase; Proteinase activated receptor 2; Pruritus; Scratch

Indexed keywords

8 BROMO CYCLIC AMP; CYCLIC AMP; ENZYME INHIBITOR; LEUKOTRIENE B4; METHYL 4 [[[3 [6,7 DIMETHOXY 2 (METHYLAMINO)QUINAZOLIN 4 YL]PHENYL]AMINO]CARBONYL]BENZOATE; PHOSPHODIESTERASE IV INHIBITOR; PROTEINASE ACTIVATED RECEPTOR 2; SLIGRL NH2; UNCLASSIFIED DRUG; ANTIPRURITIC AGENT; METHYL 4-(((3-(6,7-DIMETHOXY-2-(METHYLAMINO)QUINAZOLIN-4-YL)PHENYL)AMINO)CARBONYL)BENZOATE; OLIGOPEPTIDE; PHOSPHODIESTERASE IV; PHTHALIC ACID DERIVATIVE; QUINAZOLINE DERIVATIVE; SERYL-LEUCYL-ISOLEUCYL-GLYCYL--ARGINYL-LEUCINAMIDE; TPSAB1 PROTEIN, MOUSE; TRYPTASE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CLINICAL TRIAL (TOPIC); CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG INHIBITION; DRUG MECHANISM; ENZYME IMMUNOASSAY; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; KERATINOCYTE; MALE; MOUSE; NERVE CONDUCTION; NEWBORN; NONHUMAN; PROTEIN EXPRESSION; PRURITUS; SKIN NERVE; AGONISTS; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; CELL CULTURE; CLASSIFICATION; DRUG EFFECTS; INNERVATION; INSTITUTE FOR CANCER RESEARCH MOUSE; INTRADERMAL DRUG ADMINISTRATION; METABOLISM; SKIN; TOPICAL DRUG ADMINISTRATION;

8-BROMO CYCLIC ADENOSINE MONOPHOSPHATE; ADMINISTRATION, TOPICAL; ANIMALS; ANTIPRURITICS; CELLS, CULTURED; CYCLIC AMP; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 4; INJECTIONS, INTRADERMAL; KERATINOCYTES; LEUKOTRIENE B4; MALE; MICE; MICE, INBRED ICR; OLIGOPEPTIDES; PHOSPHODIESTERASE 4 INHIBITORS; PHTHALIC ACIDS; PRURITUS; QUINAZOLINES; RECEPTOR, PAR-2; SKIN; TRYPTASES;

EID: 84919417635     PISSN: 09231811     EISSN: 1873569X     Source Type: Journal    
DOI: 10.1016/j.jdermsci.2014.10.005     Document Type: Article

References (34)

1. Ständer S., Weisshaar E., Luger T.A. Neurophysiological and neurochemical basis of modern pruritus treatment. Exp Dermatol 2008, 17:161-169.
2. Doherty A.M. Phosphodiesterase 4 inhibitors as novel anti-inflammatory agents. Curr Opin Chem Biol 1999, 3:466-473.
3. Hoppmann J., Bäumer W., Galetzka C., Höfgen N., Kietzmann M., Rundfeldt C. The phosphodiesterase 4 inhibitor AWD 12-281 is active in a new guinea-pig model of allergic skin inflammation predictive of human skin penetration and suppresses both Th1 and Th2 cytokines in mice. J Pharm Pharmacol 2005, 57:1609-1617.
4. Bäumer W., Hoppmann J., Rundfeldt C., Kietzmann M. Highly selective phosphodiesterase 4 inhibitors for the treatment of allergic skin diseases and psoriasis. Inflamm Allergy Drug Targets 2007, 6:17-26.
5. Harada D., Takada C., Nosaka Y., Takashima Y., Kobayashi K., Takaba K., et al. Effect of orally administered KF66490, a phosphodiesterase 4 inhibitor, on dermatitis in mouse models. Int Immunopharmacol 2009, 9:55-62.
6. Akama T., Baker S.J., Zhang Y.K., Hernandez V., Zhou H., Sanders V., et al. Discovery and structure-activity study of a novel benzoxaborole anti-inflammatory agent (AN2728) for the potential topical treatment of psoriasis and atopic dermatitis. Bioorg Med Chem Lett 2009, 19:2129-2132.
7. Hanifin J.M., Chan S.C., Cheng J.B., Tofte S.J., Henderson W.R., Kirby D.S., et al. Type 4 phosphodiesterase inhibitors have clinical and in vitro anti-inflammatory effects in atopic dermatitis. J Invest Dermatol 1996, 107:51-56.
8. Ishii N., Shirato M., Wakita H., Miyazaki K., Takase Y., Asano O., et al. Antipruritic effect of the topical phosphodiesterase 4 inhibitor E6005 ameliorates skin lesions in a mouse atopic dermatitis model. J Pharmacol Exp Ther 2013, 346:105-112.
9. Furue M., Kitahara Y., Akama H., Hojo S., Hayashi N., Nakagawa H. Safety and efficacy of topical E6005, a phosphodiesterase 4 inhibitor, in Japanese adult patients with atopic dermatitis: Results of a randomized, vehicle-controlled, multicenter clinical trial. J Dermatol 2014, 41:577-585.
10. Andoh T., Yoshida T., Kuraishi Y. Topical E6005, a novel phosphodiesterase 4 inhibitor, attenuates spontaneous itch-related responses in mice with chronic atopy-like dermatitis. Exp Dermatol 2014, 23:359-361.
11. Tsujii K., Andoh T., Ui H., Lee J.B., Kuraishi Y. Involvement of tryptase and proteinase-activated receptor-2 in spontaneous itch-associated response in mice with atopy-like dermatitis. J Pharmacol Sci 2009, 109:388-395.
12. Steinhoff M., Neisius U., Ikoma A., Fartasch M., Heyer G., Skov P.S., et al. Proteinase-activated receptor-2 mediates itch: a novel pathway for pruritus in human skin. J Neurosci 2003, 23:6176-6180.
13. 2 release from keratinocytes by protease-activated receptor-2-activating peptide in ICR mice. Int Immunopharmacol 2009, 9:1332-1336.
14. 4 in spontaneous itch-related behaviour in NC mice with atopic dermatitis-like skin lesions. Exp Dermatol 2011, 20:894-898.
15. Kuraishi Y., Nagasawa T., Hayashi K., Satoh M. Scratching behavior induced by pruritogenic but not algesiogenic agents in mice. Eur J Pharmacol 1995, 275:229-233.
16. 4 in mice. J Invest Dermatol 2004, 123:196-201.
17. McCoy K.L., Traynelis S.F., Hepler J.R. PAR1 and PAR2 couple to overlapping and distinct sets of G proteins and linked signaling pathways to differentially regulate cell physiology. Mol Pharmacol 2010, 77:1005-1015.
18. Sriwai W., Mahavadi S., Al-Shboul O., Grider J.R., Murthy K.S. Distinctive G protein-dependent signaling by protease-activated receptor 2 (PAR2) in smooth muscle: Feedback inhibition of RhoA by cAMP-independent PKA. PLoS ONE 2013, 8:e66743.
19. 2, induces itch-associated responses in mice. Eur J Pharmacol 1998, 353:93-96.
20. 4 in substance P-induced itch-associated response in mice. J Invest Dermatol 2001, 117:1621-1626.
21. Luo M., Jones S.M., Phare S.M., Coffey M.J., Peters-Golden M., Brock T.G. Protein kinase A inhibits leukotriene synthesis by phosphorylation of 5-lipoxygenase on serine 523. J Biol Chem 2004, 279:41512-41520.
22. 4 or anti-inflammatory 15-epi-lipoxin a4 production. J Immunol 2008, 181:3515-3523.
23. Ricks T.K., Trejo J. Phosphorylation of protease-activated receptor-2 differentially regulates desensitization and internalization. J Biol Chem 2009, 284:34444-34457.
24. Moormann C., Artuc M., Pohl E., Varga G., Buddenkotte J., Vergnolle N., et al. Functional characterization and expression analysis of the proteinase-activated receptor-2 in human cutaneous mast cells. J Invest Dermatol 2006, 126:746-755.
25. Barreto E.O., Carvalho V.F., Lagente V., Lugnier C., Cordeiro R.S., Martins M.A., et al. Increased levels of cyclic adenosine monophosphate contribute to the hyporesponsiveness of mast cells in alloxan diabetes. Int Immunopharmacol 2004, 4:755-762.
26. Tsujii K., Andoh T., Lee J.B., Kuraishi Y. Activation of proteinase-activated receptors induces itch-associated response through histamine-dependent and -independent pathways in mice. J Pharmacol Sci 2008, 108:385-388.
27. Lakics V., Karran E.H., Boess F.G. Quantitative comparison of phosphodiesterase mRNA distribution in human brain and peripheral tissues. Neuropharmacology 2010, 59:367-374.
28. Steinhoff M., Vergnolle N., Young S.H., Tognetto M., Amadesi S., Ennes H.S., et al. Agonists of proteinase-activated receptor 2 induce inflammation by a neurogenic mechanism. Nat Med 2000, 6:151-158.
29. Jin S.L., Ding S.L., Lin S.C. Phosphodiesterase 4 and its inhibitors in inflammatory diseases. Chang Gung Med J 2012, 35:197-210.
30. Jin S.L., Conti M. Induction of the cyclic nucleotide phosphodiesterase PDE4B is essential for LPS-activated TNF-alpha responses. Proc Natl Acad Sci USA 2002, 99:7628-7633.
31. Jin S.L., Lan L., Zoudilova M., Conti M. Specific role of phosphodiesterase 4B in lipopolysaccharide-induced signaling in mouse macrophages. J Immunol 2005, 175:1523-1531.
32. H2-cell function and development of airway hyperresponsiveness in allergic asthma. J Allergy Clin Immunol 2010, 126:1252-1259.
33. Torphy T.J. Phosphodiesterase isozymes: molecular targets for novel antiasthma agents. Am J Respir Crit Care Med 1998, 157:351-370.
34. Cookson W. The immunogenetics of asthma and eczema: a new focus on the epithelium. Nat Rev Immunol 2004, 4:978-988.